



AMSTERDAM 2011 GENERAL ASSEMBLY AND SCIENTIFIC CONFERENCE

June 17th

OECI 2011


Scientific Conference

**Organising Personalised
Medicine in Oncology**

June 18th

OECI 2011

General Assembly



**WRITE THE FUTURE
THROUGH
COMPREHENSIVENESS**



eurocancercoms

www.oeci-amsterdam2011.com

OECI Welcome

The 2011 General Assembly and Scientific Meeting in Amsterdam is a unique opportunity for members to learn about the progress made by OECI in the last three years. Together with the governing bodies and the management of the Grouping, we tried to achieve a better definition of the precise role of OECI among the European oncology associations, perform a better dissemination of our initiatives and their results, and implement all the organisational changes deemed necessary to the growth of the Grouping.

Formal relations with all the main cancer organisations in Europe - such as ECCO, ESMO and EACR - have been pursued to coordinate and rationalise the respective efforts towards the creation of a European oncopolicy. From 2009, OECI has decided to participate more visibly and actively in the ECCO and ESMO conferences: the investment paid off, as our booth at these events became a crucial hub of new contacts with oncology institutes and organisations from all over the world. A new collaboration with EACR has been launched in 2010 and, as a result, a first European course in Molecular Pathology has recently been given in Amsterdam: over 120 researchers enrolled, ten of which were sponsored by an OECI award.

Moreover, OECI has contributed to the creation of a European infrastructure for Translational Research in Oncology, promoted the establishment of EurocanPlaform and participated in the FP7 research project that is well on its way, supported the educational project TRAIN and followed the ERANET TRANSCAN.

The OECI main strategic objective in these years has been to identify and perform initiatives that would help our network of CCCs to adapt to the requirements of a personalised approach to patients' care. This general direction reflected in the reorganisation and modulation of our Working Groups: now all of them are aligned either to the objective of a specific characterization of each oncologic disease (Molecular Pathology, Biobanking) or to the aim of defining accepted criteria for a CCC in Europe (Accreditation, Designation and Guidelines and Education).

In order to supply better information on the activities in place at OECI, in 2010 we signed an agreement with *ecancermedicalsecience* that has thus become the official journal of our organisation. In addition, the publication of a number of leaflets illustrating OECI as a whole or the single initiatives by the various WGs contributed to a much needed improvement in our communication capability. On another level, OECI, as a registered Publisher in 2010, produced the following titles: the *OECI Report 2009, From biobanks to research repositories, the Accreditation and designation manual* and the first of the 4 volumes of the START-OECI series on *Options and recommendations of cancer diagnosis and therapy*. Lastly, the update of our institutional logo has been followed, as many of

you will have noticed, by the revamping of the OECI website, whose design has been refreshed and streamlined.

Three years of hard work and an intense effort to improve the management of the Organisation finally bore fruit: OECI membership has grown in this period from 51 to 73 members. In the future, more and more initiatives will be put in place to strengthen this positive trend: we intend to attract more Institutes from the Countries that are already represented in the Organisation as well as to involve those that have not been involved yet.

The developments here briefly summarised have been made possible not by increased spending that might endanger the Organisation's financial safety but by a larger involvement of the OECI staff, of various member institutes and individuals of good will. In the last three years, our financial cushion has in fact doubled. This reserve both offers a guarantee to our members and an opportunity to the Board to support all the new initiatives that are deemed indispensable for the growth of the organisation.

The OECI offices are located in Amsterdam, Bari, Brussels, Genoa, Groningen, Milan, Paris, Rotterdam, e Valencia. The cooperative agreements that OECI signed with local members enable our grouping to support staff expenses indirectly, by funding the Institutes.

In May 2011, the Presidency passes on to the Netherlands, and the handover happens under good auspices: OECI is a healthy organisation, with well defined long-term plans. In order to fulfill them, however, a deeper and broader involvement of the members is necessary to obtain concrete recognition of the growing importance of the CCCs as the main infrastructure supporting the translational process and as the institution with the best expertise to advise on the definition and implementation of personalised therapies programs.

Marco A. Pierotti
President



Wim Van Harten
President Elect



OECI33 GENERAL ASSEMBLY A

Host welcome

NKI-AVL is proud to host the 33rd OECI General Assembly and Scientific Conference and to welcome our national and international guests.

The OECI has changed and gradually grown from an environment with economical and linguistic problems, to an organisation with mature tools, recognizing the challenges we face. In various countries we are determined to expand cooperation meaning to contribute to the best possible level in oncological research and care all over Europe.

Amsterdam 2011 is an excellent opportunity to emphasize the working relationship of the OECI with the major oncological institutes in Europe, strengthen the mutual ties and maybe even to initiate new ones. NKI-AVL is happy to contribute to this event.



Professor Wim van Harten

A handwritten signature in black ink, consisting of a stylized 'W' and 'H' followed by a long horizontal stroke.

On behalf of the full NKI-AVL Board

Professor A.J.M. Berns

Chairman and director of research

Professor S. Rodenhuis

Director clinical research and development

Wim van Harten

Director organization and management

Introduction to the OECI

HISTORY

The major cancer institutes of Europe often have long history and traditions which date back to the last century. Political problems, differences in economy, with more than 20 different spoken languages provided a far from favourable background for the development of an International organisation. In 1977, in Vienna, on the occasion of the anniversary of the local Cancer Research Institute, a historic meeting involving many European Institutes' directors convened. For the very first time, the attendants were willing to promote greater cooperation among the European cancer centres and institutes in the field of cancer control, data collection and dissemination, as well as in collaborative research. This meeting, unique in the history of European oncology, was the starting point for new and dynamic inter institutional collaborative efforts in Europe. In fact, during a second meeting of European cancer institutes' directors in Dubrovnik, Yugoslavia, on 14 May 1979, the "Organisation of European Cancer Institutes" was founded. This date marks the real starting point of the OECI.

FROM THE OECI TO THE EUROPEAN ECONOMIC INTEREST GROUPING "OEI"

20 years after its foundation, in 1999, the OEI Programme Committee launched the idea of setting up a grouping of selected European Comprehensive Cancer Centres. On November 17th, 2000 after a conference titled "Towards a European Space for Oncology", the European Economic Interest Grouping "Liaison Network for Cancer, the EEIG-LINC was created in Brussels, with the main aim to support the participation of the OEI in building the European Area for Cancer Research.

In 2004, the OEI and the EEIG-LINC Boards decided to merge in one Association and, at the Berlin General Assembly, the EEIG-LINC was transformed into the EEIG-OEI, giving birth to the actual Organisation and providing the right setting and the appropriate note of informality to overcome those political, cultural, and language barriers which, for so long, frustrated a profitable and comprehensive working relationship between European major cancer institutes.

ORGANISATION

The OEI is a continuously growing and developing network, presently regrouping 73 cancer centres and institutions across Europe. The OEI is dynamically working in crosscut expertise projects organised mainly within Working Groups. Currently, there are four main Working Groups and three activities financed through membership fees and also supported by external funding bodies.

THE MISSION

In recent years, like most European scientific societies, the OEI had to reconsider its mission, its internal organisation and its strategies in order to better respond to the

changing needs and expectations of the citizens and of its own members. The creation of the European Research Area requires mandatory steps to sustain a rapid transfer of innovation. The translational research path becomes the core of the OECI program as a guarantee of innovation and competitiveness of health services offered by OECI institutes. The route leading from the scientific discovery to the product will, therefore, determine changes within the organisation. The ability to compete and to innovate is precisely the characteristic of a comprehensive cancer centre, which must be able to demonstrate its potential to become a landmark for the area in which it operates and to interact with health professionals in order to transfer diagnostic and therapeutic methods and explore new application areas. The activities developed in the last years represent the results of the occurred transformation and demonstrate how the Organisation has focused its mandate on the promotion of translational research in oncology.

OECI IN THE FUTURE

The OECI outlook for the coming years is mainly to strengthen its organisational system in order to promote and to increasingly sustain its role as carrier system to concrete support innovation in Europe. At this purpose, the Accreditation and Designation project and the guidelines for the management of a CCC, will represent one of the major tasks for the coming years as well as the guarantee of a more rapid process of innovation uptake within the network. The OECI will continue on its path, promoting a management system for cancer institutes based on an entrepreneurial approach: keeping an active role in the European scenario and having a transparent and rigorous management system based on identifiable and transferable methodologies not affected by an unprepared decision-making approach.



The OECI board

PRESIDENT

Marco A. Pierotti

Italy

Fondazione IRCCS Istituto Nazionale Tumori - Milan

PRESIDENT ELECT

Wim H. Van Harten

The Netherlands

Netherlands Cancer Institute - Amsterdam

FORMER PRESIDENT

Ulrik Ringborg

Sweden

Karolinska Institute - Stockholm

EXECUTIVE SECRETARY

Guy Storme

Belgium

Oncology Centre UZ Brussel - Brussels

ELECTED MEMBER-TREASURER

Josè Maria Laranja Pontes

Portugal

Instituto Portugues de Oncologia Francisco Gentil EPE - Oporto

ELECTED MEMBER

Julio Celis

Denmark

Danish Cancer Society - Copenhagen

SPECIAL ASSISTANT TO THE PRESIDENT

Claudio Lombardo

Italy

Head Liaison Office and Coordinating Secretariat
IST - National Institute for Cancer Research - Genoa

Co-opted Members to the Board

Antonio Llombart-Bosch

Spain

Fundacion Instituto Valenciano de Oncologia - Valencia

Molecular Pathobiology Working Group Chairperson

Angelo Paradiso

Italy

IRCCS Ospedale Oncologico - Bari

Education and Training Working Group Chairperson

Peter Riegman

The Netherlands

Erasmus Hospital - Rotterdam

Cancer Biobanks Working Group Chairperson

Mahasti Saghatchian

France

Institut Gustave Roussy - Villejuif

Accreditation Working Group Chairperson

Lisa Licitra

Italy

Fondazione IRCCS Istituto Nazionale Tumori - Milan

Start Activity Chairperson

Claudio Lombardo and **Gordon Mc Vie**

OEI and ecanermedalscience

Dissemination and Communication Activity Chairpersons

Thomas Tursz

France

Institut Gustave Roussy - Villejuif

WIN Consortium Activity Chairperson

Dominique de Valeriola

Belgium

Institut Jules Bordet - Brussels

The OECI membership

Belgium

- **Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles**
Brussels
- **Oncologic Center**
UZBrussel, Brussels
- **Cliniques Universitaire Saint-Luc**
(Centre du Cancer), Brussels

Bulgaria

- **National Oncological Hospital**
Sofia

Czech Republic

- **Masaryk Memorial Cancer Institute**
Brno

Denmark

- **Danish Cancer Society, Institute of Cancer Biology**
Copenhagen

Estonia

- **North Estonia Medical Centre**
Tallinn
- **Tartu University Hospital**
Tartu

Finland

- **Helsinki University Central Hospital**
Helsinki

France

- **Centre Alexis Vautrin**
Nancy
- **Centre G.F. Leclerc**
Dijon
- **Centre Leon Berard**
Lyon
- **Centre Paul Strauss**
Strasbourg
- **Institut Curie**
Paris
- **Institut Gustave Roussy**
Villejuif
- **Centre Antoine Lacassagne**
Nice
- **Centre Henri Becquerel**
Rouen
- **Centre Paul Papin CRLCC**
Angers
- **Institut Sainte Catherine**
Avignon
- **Institut Claudius Regaud**
Toulouse

Germany

- **Deutsches Krebsforschungszentrum**
Heidelberg
- **University Cancer Centre Dresden Carl Gustav Carus**
Dresden
- **Charité Comprehensive Cancer Center**
Berlin

Greece

- **Agii Anargiri General Oncological Hospital of Kifissia**
Athens
- **'Agios Savvas' Regional Cancer Hospital**
Athens
- **Metaxa' Cancer Hospital of Piraeus**
Piraeus

Hungary

- **National Institute of Oncology**
Budapest

Italy

- **Centro di Riferimento Oncologico (CRO) Istituto Nazionale Tumori**
Aviano
- **European Institute of Oncology (IEO)**
Milan
- **European School of Oncology (ESO)**
Milan
- **Fondazione IRCCS Istituto Nazionale Tumori (INT)**
Milan
- **Fondazione San Raffaele**
Milan
- **IST Istituto Nazionale per la Ricerca sul Cancro**
Genoa
- **Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione 'G.Pascale'**
Naples
- **Istituto Regina Elena (IRE)**
Rome
- **Istituto Superiore di Oncologia (ISO)**
Genoa
- **Istituto Tumori Giovanni Paolo II**
Bari
- **Istituto di Ricerche Farmacologiche Mario Negri IRFMN**
Milan
- **Istituto di Ricerca e Cura del Cancro di Candiolo**
Turin
- **Istituto Oncologico Veneto (IOV)**
Padua

- **Istituto FIRC di Oncologia Molecolare (IFOM)**
Milan
- **Centro di Riferimento Oncologico della Basilicata (CROB)**
Potenza
- **Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)**
Meldola - Forlì

Lithuania

- **Institute of Oncology, Vilnius University**
Vilnius

Norway

- **Rikshospitalet-Radiumhospitalet Medical Center**
Oslo

Poland

- **Wielkopolskie Cancer Centre**
Poznan

Portugal

- **Instituto Portugues de Oncologia Francisco Gentil EPE do Porto**
Oporto
- **Instituto Portugues de Oncologia Francisco Gentil EPE do Coimbra**
Coimbra
- **Instituto Portugues de Oncologia Francisco Gentil EPE do Lisboa**
Lisbon

Romania

- **Oncology Institute 'Prof. Dr. Ion Chiricuta'**
Cluj-Napoca
- **Institute of Oncology 'Prof. Dr. Al Trestioreanu'**
Bucharest

Russia

- **Blokhin Russian Cancer Research Centre**
Moscow
- **Clinical Cancer Centre**
Kazan

Serbia - Montenegro

- **Institute of Oncology Sremska Kamenica Novi Sad**
Smremska Kamenica

Slovakia

- **Slovak Comprehensive Cancer Centre**
Bratislava

Slovenia

- **Institute of Oncology Ljubljana**
Ljubljana

Spain

- **Centro Nacional de Investigaciones Oncologicas**
Madrid
- **Institut Català d'Oncologia**
Barcelona
- **Instituto Madrilenio de Oncologia (IMO)**
Madrid
- **Fundacion Instituto Valenciano de Oncologia (IVO)**
Valencia

Sweden

- **Salgrenska University Hospital**
Göteborg
- **The Karolinska University Hospital and Institute**
Stockholm

Switzerland

- **Istituto Oncologico Svizzera Italiana (IOSI)**
Bellinzona

The Netherlands

- **Erasmus MC Daniel den Hoed Cancer Centre**
Rotterdam
- **Integral Kankercentrum Noord-Nederland**
Groningen
- **The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital**
Amsterdam
- **Maastricht University Medisch Centrum**
Maastricht

Turkey

- **Dokuz Eylül University Institute of Oncology**
Izmir

Ukraine

- **R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology**
Kiev

United Kingdom

- **Cancer Research UK Cambridge Research Institute**
London
- **Christie Hospital NHS Foundation Trust**
Manchester
- **King' s Health Partners Integrated Cancer Centre**
London

The Netherlands Cancer Institute

The Netherlands Cancer Institute was established on October 10, 1913. The founders wanted to create a cancer institute 'where patients suffering from malignant growths could be treated adequately and where cancer and related diseases could be studied'. They bought a house on one of the canals in Amsterdam and named it the 'Antoni van Leeuwenhoek Huis', after the famous Dutch microscopist. The clinic had room for 17 patients, while the laboratory could accommodate 8 to 10 scientists.

Nowadays, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital is a Comprehensive Cancer Center, combining hospital and research laboratories under one roof in a single independent organization and maintains an important role as a national and international center of scientific and clinical expertise, development and training.

The hospital comprises 180 beds, an outpatient clinic and a large radiotherapy department. Facilities for clinical research include a large patient database, clinical data management, extensive diagnostic facilities, a pharmacy with a production unit for experimental drugs, and active research groups in pharmacy, epidemiology and psychosocial oncology. The laboratory covers all major areas of cancer research, with special emphasis on cell-based screens, mouse tumour models, cell biology, structural biology, and immunology. Translational research is an integral activity of many research groups and is fostered by collaborations between clinical and basic scientists.

NKI-AVL saw close collaboration between scientists and clinicians as essential to fighting cancer. This has led to many important discoveries and improved therapies.

The basic research at the NKI aims for a more profound understanding of how cancer arises, and strives to translate this knowledge into new approaches to diagnosing and treating cancer. This encompasses many scientific themes in tumor-cell biology, notably how genetic mutations arise, in which genes, and with what consequences; how genes are organized in the nucleus and regulated, and how this regulation may go wrong in cancer; signaling in normal and cancer cells – at the cell surface and the transmission of signals to the cell interior; cell fate; cell division; programmed cell death (apoptosis); tumor growth and metastasis; and resistance to cancer treatment.

Cutting-edge technologies

The NKI has particular expertise in using and generating new animal models for cancer. These are helping to provide insights into many aspects of cancer biology, especially in understanding how the effects of different genetic mutations can combine to promote tumour development. They also serve as tools for the pre-clinical testing of new therapies and drugs. The NKI's animal models are valuable not only to NKI researchers but also to other research institutes and pharmaceutical companies for the testing of new anticancer drugs.

The NKI has a collection of over 30,000 small RNA pieces, which in total correspond to all

human genes. Besides contributing to understanding gene function, this technique also helps to identify new targets for drug development.

NKI scientists are investigating the effects of genetic mutations on processes that normally maintain cells in good health. Using in vitro cell culture, functional screens, biochemistry and protein crystallography, NKI scientists are investigating the processes leading to DNA damage or replication errors, and the effects of mutations on DNA repair proteins.

The NKI-AVL is proud of its position as one of The Netherlands' foremost biomedical research institutions, dedicated to improving the treatment and care of patients with cancer, and helping healthy individuals to avoid cancer in future. Its clinical services operate to the highest international standards, and continue to extend the boundaries of what can be done for cancer patients, always considering the quality of life. Its scientific achievements are celebrated internationally through awards and highly cited publications in peer-reviewed journals. With well-integrated clinical and basic research operations, the NKI-AVL aims to have a critical impact on cancer in the future.

Top oncology centre

The NKI-AVL diagnoses and treats cancer patients from all over the Netherlands and takes a multidisciplinary approach to the diagnosis and treatment of cancer.

25 percent of the care provided consists of highly sophisticated cancer treatment, while 60 percent of patients are referred to the institute by specialists in other parts of the country and 15 percent relates to care for patients from the Amsterdam region.



AND SCIENTIFIC CONFERENCE

NKI-AVL specialists have access to a wide range of facilities for the diagnosis of cancer. The departments of pathology, radiology and nuclear medicine and the clinical laboratory use many different diagnostic tools. The Familial Tumour Clinic investigates the risk of hereditary forms of cancer with the aid of questionnaires, interviews and if necessary, DNA diagnosis.

Specialised treatments

Many different specialised treatments are provided at the NKI-AVL. These include Robotic assisted surgery. The NKI-AVL was one of the first organisations in the Netherlands to operate with the Da Vinci Robot. An innovative continuously operational operating room center is being developed at present. Furthermore pharmaceutical trials and translational research projects are launched for instance in the field of immunological treatments for melanoma or microarray guided treatments.



OEI33 GENERAL ASSEMBLY A

General timetable

June 16 The Netherlands Cancer Institute		
MORNING	OEI Board <i>Room 1</i>	Accreditation and Designation E-tool training <i>Room 5</i>
Lunch		
AFTERNOON	Coordination of Patient Education Activities in Europe: an OEI-ECPC initiative <i>Room 5</i>	Accreditation and Designation Steering Committee <i>Room 1</i>
EVENING	Dinner of Board and invitees	

	June 17 Hotel Barbizon Palace	June 18 The Netherlands Cancer Institute
MORNING	OEI 2011 Scientific Conference <i>Organising Personalised Medicine in Oncology</i>	OEI 2011 General Assembly (Restricted to Members only)
Lunch		
AFTERNOON	OEI 2011 Scientific Conference <i>Organising Personalised Medicine in Oncology</i>	OEI 2011 General Assembly (Working Groups and Activities presentations)
EVENING	Gala Dinner	

OECI E&T Steering Committee Meeting

Coordination of Multidisciplinary Education Activities in Europe: the Perspective of the Physicians, the Nurses and the Patients

June 16th

The Netherland Cancer Institute

Plesmanlaan 121,
1066 CX Amsterdam

An OECI-ECPC Initiative

MEETING PROGRAMME

- 14.30 Introduction: **Angelo Paradiso** and **Tom Hudson**
“Speaking with one voice at the European level”
- 14.45 **Session 1: Educational Activities in Europe**
The Initiatives of Different Societies
Chair: **Linda Cairns**
- Presentations from:
- **ESSO** **Beate Rau**, ESSO Education Committee
 - **ESTRO** **Christine Verfaillie**, Manager ESTRO School
 - **EAPC** **Pam Firth**, EAPC Board Member
 - **EONS** **to be confirmed**
 - **ECPC** **Tom van der Wal**, ECPC Board
 - **OECI** **Paolo De Paoli**, OECI E&T Working Group Steering Committee
- 16.00 **Session 2: Interactive Patient Portal Projects in the Netherlands**
- **Presentation: Research & Development (ACARE2MOVE)**
project of **NKI Wilma Kuijpers**, **Wim Groen**
 - **Site Demonstration: NIPED/Oncokompas Self management and stepped care** **C.K. van Kalken**, **R. Kraaijenhagen**
- 16.30 **Session 3: Round Table**
Moderators: **Viorica Cursaru** & **Paolo De Paoli**
- Part 1: Cooperation – what?**
- **What are the potential benefits of cooperating on a European level?**
 - **Which means of education are suitable for collaborative efforts?**
 - **How can we achieve integrated patient focus and involvement?**
- Part 2: Cooperation – how?**
- **What types of cooperation are preferred?**
 - **What are the different roles of the various stakeholders involved?**
 - **What are the potential structures and logistics of this cooperation?**
 - **What are the likely obstacles and how can they be addressed?**
- 17.15 Conclusions: **Tom Hudson**, **Francesco de Lorenzo** and **Angelo Paradiso**
What is the next step for multidisciplinary, patient-focused education?

June 16th

The Netherland
Cancer Institute

Plesmanlaan 121,
1066 CX Amsterdam

LIST OF SPEAKERS AND AFFILIATIONS

Linda Cairns	Science Editor, <i>ecancermedicalsecience</i> , Bristol, United Kingdom
Viorica Cursaru	Myeloma Euronet, Romania
Francesco de Lorenzo	F.A.V.O. President, Italy
Paolo De Paoli	Scientific Director CRO Aviano, Italy; OECI E&T WG Steering Committee
Pam Firth	Consultant and Teacher in Psychosocial Palliative Care, Welwyn Garden City, United Kingdom; EAPC Board
Wim Groen	Researcher – Physcosocial Research and Epidemiology, NKI Amsterdam, The Netherlands
Tom Hudson	Europa Uomo, Men Against Cancer (MAC), Ireland; ECPC President
R. Kraaijenhagen	Medical Director, NIPED, The Netherlands
Wilma Kuijpers	phD student, NKI Amsterdam, The Netherlands
Angelo Paradiso	Scientific Director NCI Bari, Italy; Chair of OECI E&T WG
Tom van der Val	Stichting Diagnose Kanker; ECPC Board Member
Beate Rau	The Charité, Berlin, Germany; ESSO Education Committee
C.K. van Kalken	Managing Director, NIPED, the Netherlands
Christine Verfaillie	Manager of ESTRO School, Brussels, Belgium

AND SCIENTIFIC CONFERENCE

Welcome to the OECl Scientific Conference “Organising Personalised Medicine in Oncology”

June 17th

**Hotel
Barbizon**

**Prins Hendrikkade 59,
Amsterdam**

The main objective of the OECl is to improve the quality of oncologic care and research in Europe with the aim to reduce mortality and morbidity related to cancer. The strategic priorities of the OECl in the coming years are to include a major part of its members into the accreditation designation program and to add outcome measurement to this schedule.

Furthermore it is important that the visibility of the OECl at European level improves and that the European commission starts to embrace the role of comprehensive cancer centers, ultimately and in combination with national stimulation programs contributing to sustainable financing for platforms of translational research in oncologic care.

In view of the increasing importance of organization and infrastructure in oncologic care and research, organizational quality is increasingly becoming an issue. In order to strengthen the operational structure that facilitates translational research and integrated care, OECl will focus on related issues. Such as the role and integration of molecular pathology , organizing translational research and developing survivorship care.

The title of the 2011 Scientific Conference is “Organizing Personalized Medicine in Oncology”. This emphasizes that personalized medicine is an important development. Due to the complexity of multidisciplinary care, the infrastructure and expertise needed for translational research and medicine, it is important to additionally focus on organizing personalized medicine.

For the 2011 Amsterdam Scientific Conference we put together a program which is covering a wide variety of topics, ranging from tumor service related, through translational infrastructure and organizational issues. We expect an audience of not only representatives of OECl members but also from other interested organizations.

We hope the offered program is interesting and hope to meet you all in June in Amsterdam.

We are honored to welcome you!

OECD Scientific Conference

MORNING SESSION

8.30 Registration

8.45 **Welcome addresses**

Wim van Harten and **Marco A. Pierotti**

Dutch Ministerial view

Representative of Dutch Ministry of Health

Cancer research: a challenge for the E.U.

Jan van de Loo - Health Directorate E.C.

9.30 **SESSION 1: Targeted therapies and personalised medicine**

Chair: **Alexander Eggermont**

State of the art and perspective from research viewpoint

René Bernards

State of the art and perspective from clinical viewpoint

Peter Schlag

State of art and perspectives of biomarkers application in personalized medicine

Massimo Gion

10.45 Coffee Break

11.00 **SESSION 2: Translating research into personalised care**

Chair: **Marco A. Pierotti**

Synergy among Breast Units: The SenoNetwork Project

Carlos Garcia Etienne

Prostate cancer units

Riccardo Valdagni

Advanced melanoma treatment

John Haanen

Discussion

12.30 Lunch

AFTERNOON SESSION

13.30 **SESSION 3: Organizing research / translational research facilities**

Chair: **Ulrik Ringborg**

European Advanced Translational Research Infrastructure in Medicine (EATRIS)

Guus van Dongen

European Clinical Infrastructure Network (ECRIN) Program Coordinator

Jacques Demotes-Mainard

Molecular genetics services

Christof von Kalle

15.15 Coffee Break

June 17th

**Hotel
Barbizon**

**Prins Hendrikkade 59,
Amsterdam**

15.15 SESSION 4: **Quality assurance and internal management**
Chair: **Wim van Harten**

Quality assurance in translational oncological research
Chris Harrison

Quality management in multidisciplinary care and radiotherapy

Truus Reynders

Accreditation, Designation and organising benchmarking services for EU Cancer Centers

R. Sullivan / M. Saghatchian

Rethink the management of a CCC: an obliged path for quality and personalized medicine

Alexander Eggermont

June 17th

**Hotel
Barbizon**

**Prins Hendrikkade 59,
Amsterdam**

17.00 Closing discussion

SCIENTIFIC COMMITTEE

Marco A. Pierotti, INT, Italy

Wim van Harten, NKI, The Netherlands

Anton Berns, NKI, The Netherlands

René Bernards, NKI, The Netherlands

Julio Celis, Danish Cancer Society, Denmark

Josè L. Pontes, Instituto Portugues de Oncologia, Portugal

Ulrik Ringborg, Karolinska Institute, Sweden

Guy Storme, UZ Brussels, Belgium

PARTICIPANTS

René Bernards, Molecular Carcinogenesis, Netherlands Cancer Institute, The Netherlands

Jacques Demotes-Mainard, ECRIN Programme Coordinator, France

Alexander Eggermont, Institut Gustave Roussy, France

Carlos Garcia Etienne, Seno Network Scientific Coordinator, ESO, Switzerland

Massimo Gion, Editor in chief International Journal of Biological Markers, Italy

John Haanen, Immunology, Netherlands Cancer Institute, The Netherlands

Chris Harrison, Medical Director, Christie Hospital NHS Foundation Trust, United Kingdom

Marco A. Pierotti, Fondazione Istituto Nazionale Tumori, Italy

Truus Reynders, AZ-VUB Cancer Centre, Belgium

Ulrik Ringborg, Karolinska Institute, Sweden

Mahasti Saghatchian, Institut Gustave Roussy, France

Peter Schlag, Director of Charité Comprehensive Cancer Center, Germany

Richard Sullivan, Kings health partners integrated cancer centre, United Kingdom

Jan van de Loo, DG Research - Health Directorate

Guus van Dongen, EATRIS, VU Medisch Centrum Amsterdam, The Netherlands

Wim van Harten, Director Organization and Management, Netherlands Cancer Institute, The Netherlands

Riccardo Valdagni, Director Prostate Cancer Program, Fondazione INT, Italy

Christof von Kalle, German Cancer Research Center (DKFZ), Germany

ORGANISING COMMITTEE

Claudio Lombardo - OECI/IST

c/o Istituto Nazionale per la Ricerca sul Cancro - Genoa, Italy

Tel: +32 2 512 01 46

Email: oeci@oeci.eu - <http://www.oeci.eu>

Georgette van Velzen - The Netherlands Cancer Institute

Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

Tel: +31 20 5129022

Email: g.v.velzen@nki.nl - <http://www.oeci-amsterdam2011.com>

OECI33 GENERAL ASSEMBLY A

OECI General Assembly

MORNING SESSION

8.30 *Registration*

8.50 **General Assembly constitution and President addresses**

9.00 **Session 1: Administrative and financial matters**

Chairs: Marco A. Pierotti and Wim van Harten

Point 1: Approval of the Agenda
Marco A. Pierotti

Point 2: Approval of the June 17th 2010 General Assembly's Minutes (vote requested - **decision taken at the simple majority** of the votes of the OECI full members present or represented)
Marco A. Pierotti

Point 3: Point 3: Approval of the Financial Statement 2010 (vote requested – **decision taken at the simple majority** of the votes of the OECI full members present or represented)
Guy Storme

Point 4: 2011 Provisional Budget (vote requested – **decision taken at the simple majority** of the votes of the OECI full members present or represented)
José Laranja Pontes

Point 5: OECI Board revision of composition and tasks assigned (vote requested – **decision taken at the unanimity** of the votes of the OECI full members present or represented)
Marco A. Pierotti

Point 6: New affiliations and resignations of Members (vote requested – **decision taken at the unanimity** of the votes of the OECI full members present or represented)
Guy Storme

Ceremony for the delivery of OECI European Accreditation Certificates

Mahasti Saghatchian and Wim van Harten

11.00 *Coffee break*

11.15 **Session 2: the OECI Philosophy for the coming years**

Chairs: Wim van Harten and Julio Celis

Point 7: OECI 2011- 2014 Presidency Program - Proposal for the constitution of an OECI Council - Proposal for the venue of the General Assemblies for the coming years
Wim van Harten

Point 8: OECI – AACI cooperation program
Guy Storme

The OECI contribution to the building of the European Area for Translational Cancer Research (Point 9 and 10)

June 18th

**The Netherland
Cancer Institute**

**Plesmanlaan 121,
1066 CX Amsterdam**

Point 9: EurocanPlatform NoE
Ulrik Ringborg

Point 10: ERANET TRANSCAN - TRAIN mobility project
EUROCANCERCOMS – eCancerHub
Claudio Lombardo and Gordon McVie

12.30 Lunch

AFTERNOON SESSION

13.30 **Working Groups and Activities reports**
Chairs: Alexander Eggermont and Guy Storme

13.30 Accreditation and Designation Project: *Mahasti Saghatchian*

13.50 Education and Training: *Angelo Paradiso*

14.10 Biobanks and Molecular Pathology WGs: *Peter Riegman and Antonio Llombart-Bosch*

14.30 The European Options and Recommendations of Diagnosis and Therapy: *Lisa Licitra*

14.45 Dissemination activities: *Claudio Lombardo*

15.00 Cancer prevention: a practical proposal for OECl collaborating activities: *Chris Harrison*

15.15 - 15.30 **Discussion and closing of the 2011 OECl General Assembly**
Wim van Harten

SPEAKERS

Julio Celis

Danish Cancer Society, Institute of Cancer Biology, Copenhagen - DK

Alexander Eggermont

Institut Gustave Roussy, Paris - F

Chris Harrison

Christie Hospital NHS Foundation Trust, Manchester - UK

José Laranja Pontes

Instituto Portugues de Oncologia do Porto Francisco Gentil, Porto - P

Lisa Licitra

START Project – Fondazione IRCCS Istituto Nazionale dei Tumori, Milan - I

Antonio Llombart Bosch

Fundacion Instituto Valenciano de Oncologia (IVO) - SP

Claudio Lombardo

Istituto Nazionale per la Ricerca sul Cancro, Genoa - I

Gordon McVie

European Institute of Oncology, Milan - I

Angelo Paradiso

Istituto Oncologico Bari - I

Marco A. Pierotti

Fondazione IRCCS Istituto Nazionale Tumori, Milan - I

Peter Riegman

Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam - NL

Ulrik Ringborg

Karolinska Institute, Stockholm - S

Mahasti Saghatchian

Institut Gustave Roussy, Paris - F

Guy Storme

Oncology Centre UZ Brussel - BE

Wim van Harten

Nederlands Kanker Instituut (NKI), Amsterdam - NL

June 18th

**The Netherland
Cancer Institute**

**Plesmanlaan 121,
1066 CX Amsterdam**

OECI33 GENERAL ASSEMBLY A

Amsterdam general information

Amsterdam, the city

Amsterdam is one of the greatest small cities in the world. From its canals to world-famous museums and historical sights, Amsterdam is one of the most romantic and beautiful cities in Europe.



It has more canals than Venice

Amsterdam's watery maze of canals could be considered its most distinguishing - and most charming - feature. But when people refer to the city as 'The Venice of the North', what they may not realise is that the tree-lined channels outnumber the lagoon-filled lanes of our Italian cousin (Amsterdam also has about three times as many bridges, more than 1200).



AND SCIENTIFIC CONFERENCE

Museums

When you measure per square metre, Amsterdam boasts more museums than any other city in the world. It seems like there is a museum around every corner. The Dutch capital is home to more than 40 museums and galleries and the layout of the city makes sightseeing on foot quite easy, with most of the museums situated close together on the area known as 'Museumplein' or along the main canal ring.



Museum Quarter

Amsterdam is an unconventional and captivating city, with an unusual and intriguing past. It's therefore quite fitting that the city should have an exciting – and even entertaining – museum dedicated to its history. The Amsterdam Museum (formerly known as the Amsterdam Historical Museum) is a fascinating place to get a glimpse of Amsterdam's chequered and colourful past.

A visit to the Amsterdam Museum gives visitors a really good understanding of why Amsterdam is here, how the city grew from a small medieval town to a world-famous city and recounts the major events that occurred here. And best of all, it does this in a fun and interactive way. There are masses of exhibits, loads of interactive displays, films in Dutch and English and some beautiful paintings and other city gems – like the intriguingly-named "Snotnose" barrel organ!

Museum Quarter Attractions

Located near the Museumplein, the Museum Quarter (Museumkwartier) is certainly the place for culture vultures to be in Amsterdam. The quarter is home to the Rijksmuseum, Van Gogh museum, Concertgebouw (Concert Hall) and the Vondelpark. If that's not enough, then there's also the Dutch Film museum and Coster Diamonds, which gives free tours of its factory, to amuse and amaze you. Most of the buildings in this attractive quarter are from the 19th century and both Museumplein and the Vondelpark are great for picnics and lazing on the grass.



OECSI33 GENERAL ASSEMBLY A

Highlights of the Van Gogh Museum

With several of Van Gogh's famous works on display at the museum, it's difficult to know where to start. Highlights of the collection include *The Potato Eaters*, *Bedroom in Arles*, *Blossoming Almond Tree* and of course *Still Life: Vase with Twelve Sunflowers*. As the museum gives such an excellent account of the artist's life, visitors also glean important information into the background of the paintings. For instance, *Bedroom in Arles* was a depiction of Van Gogh's bedroom in his Yellow House and he details his artistic intentions in a letter to Theo.

The Hortus Botanicus

The Hortus Botanicus Amsterdam is one of the oldest botanic gardens in the world. Located in the leafy Plantage district, the garden is a quiet and relaxing paradise. More than 4,000 plant species grow here and you'll be amazed by both the flora and the variety of attractive display areas.

Founded in 1638, the Hortus was originally a medicinal herb garden, where doctors and pharmacists were trained. Later, as the Dutch brought back exotic plants from their sailing expeditions the Hortus gained a rich collection from around the world. The "crown jewels" include a more than 300-year old Eastern Cape giant cycad and *Coffea arabica* (Arabian coffee) where a single plant from the Hortus sowed the seeds for an economically important trade. The Hortus also played a large role in the distribution of the oil palm – another plant widely-used in production.

Culinary Amsterdam

A visit to Amsterdam is not only a feast for the eyes but a feast for the taste buds as well. With its many cultural influences, it is a place which offers a varied selection of cuisines to both challenge and satisfy the palate. There are hundreds of restaurants to experience and lots of exotic foods to try. From Dutch to Ethiopian, it is an adventure in eating that will open doors to another world. Which restaurants you will prefer is not only decided by your taste but also your choice of quality, your budget, location and atmosphere.



AND SCIENTIFIC CONFERENCE

De 9 Straatjes (The 9 Streets)

Between Leidsestraat and Raadhuisstraat there is an area known as De 9 Straatjes (The 9 Streets), named after the nine side streets connecting the main canals. Together they constitute an appealing neighbourhood full of unique shops, wonderful places to have lunch and a great atmosphere.



Shopping

The Museum District (Rijksmuseum, Van Gogh Museum and Stedelijk Museum) is home to the majority of Amsterdam's luxury boutiques and designer stores. The P.C. Hooftstraat is Amsterdam's most upscale and exclusive shopping street. Along three short blocks is every label and designer you desire: Chanel, Louis Vuitton, DKNY, Mulberry, Ralph Lauren, Tommy Hilfiger and more. On the Van Baerlestraat there is a large Vanillia (popular Dutch brand) store. Famous Dutch designers Percy Irausquin and Marlies Dekkers have shops on the Cornelis Schuytstraat.

The two main shopping streets in Amsterdam's city centre are the Kalverstraat and the Leidsestraat. Of the two, the Leidsestraat has the more exclusive shops such as Filippa K, Karen Millen, Paul Warmer and Shoebaloo. The Kalverstraat is home to all the shops you would expect in a large city like H&M, Mexx, Zara and Miss Sixty. There are also several department stores here.

Markets

Visiting open-air markets is one of the best ways to soak up authentic culture in a travel destination. Amsterdam's markten (markets) are alive with the colours, smells and sights that define the local flavour here. Discover our village of neighbourhood markets, most of which are open year-round, rain or shine.

Albert Cuyp Market

More than 250 stalls sell everything from cheese to bike chains, fresh produce to fried street snacks, shaving cream to shoes and clothes. A feast for the senses, this is Amsterdam's busiest market.

When: Year-round, Monday - Saturday 09:00 - 17:00

Where: Albert Cuypstraat, De Pijp

What's close: Heineken Experience, Sarphatipark



OECSI33 GENERAL ASSEMBLY A

Dappermarkt

Voted best market in the Netherlands 2007/2008, this is also considered as Amsterdam's most affordable and most multicultural market. Sample exotic foods, try on a funky dress, or buy some bread and cheese for a picnic in the park.

When: Year-round, Monday - Saturday 09:00 - 17:00

Where: Oost (East)

What's close: Artis Zoo, Tropenmuseum, Oosterpark

Flower Market (Bloemenmarkt)

Those who want to witness the long Dutch tradition of flower trading should visit this canal-side alley full of blooms, bulbs and plants. No matter what time of year, the stalls create seasonal scents and a lush rainbow of choices.

When: Year-round, Monday - Saturday 09:00 - 17:30, Sunday 11:00 - 17:00

Where: Central Canal District

What's close: Tuschinski Theatre, 9 Streets (shopping)

Waterlooplein

A bargain-hunter's or junk collector's paradise, this sprawling flea market is worth a visit just for the spectacle. Some stalls specialize in bric-a-brac and used goods, others in new clothes and cheap toys.

When: Year-round, Monday - Saturday 09:00 - 18:00

Where: Central Canal District

What's close: Muziektheater, Rembrandthuis, Portuguese Israeli Synagogue, Moses and Aaron Church

Dutch currency

As in most European countries, the currency of the Netherlands is the Euro (symbolised as EUR or €). Other currencies are normally not accepted, make sure you change your dollars or other foreign currencies at one of the currency exchange offices located throughout the city. Most shops and restaurants in Amsterdam accept credit cards, but not all. It is therefore recommended to either ask before you order or ensure you have a sufficient amount in cash to cover the bill.

General opening hours

Shops are open from Monday to Saturday, 9:00 to 18:00 (Saturday until 17:00 and Thursday evenings until 21:00). Sundays 12:00 to 17:00. Some supermarkets stay open until 20:00 or 22:00 on week nights. Most businesses operate Monday to Friday, 8:30 to 17:00. Banks are open weekdays only, between 9:00 and 16:00. Post offices are open weekdays only, between 9:00 and 17:00. The main post office on Singel 250 basement is open weekdays between 7:30 and 18:30 and also open Saturdays from 07:30 to 17:00

Telephone

Most local telephones are card-operated. Telephone cards are available at post offices, tobacco stores and several tourist offices. The international access code to call abroad from the Netherlands is 00, plus the code of the country you wish to call. When calling Amsterdam from abroad, dial 0031 (for Holland) and 20 (for Amsterdam).

Internet

If you are a guest of a hotel, you can often use their wireless internet. And more and more cafes are now also offering wireless internet, which you can access with your own laptop. Some places



AND SCIENTIFIC CONFERENCE

offer this service free of charge, while in others you have to pay. If you don't have a laptop you can use one of the internet cafes in the city.

Tipping

Service is always included. It is however customary to tip in restaurants, bars and when paying for taxis. As a general rule tipping between 5 - 10% is acceptable.

Accessible Amsterdam

Download and print the practical Accessible Amsterdam map before you arrive in the city (please note that the leaflet contains 2010 information with old prices). More than just a map, it also features information on where to park (and the costs involved) as well as information on public transport and bike rental. The accessibility map contains everything you need to explore the city trouble free!

Getting around in Amsterdam

Amsterdam boasts an impressive public transport network including metros, buses, trams, ferries and trains to help you get around the capital.

Tourist Offices Amsterdam:

Stationsquare

020-201 8800

Monday - Saturday 09:00-18:00, Sunday 09.00-17.00

Stationsplein10

Across from Central Station Amsterdam, Noord-Zuid Hollands Koffiehuis

Holland Tourist Information

020-201 8800

Monday - Sunday 07:00-22:00

Schiphol Airport, Arrivals 2

At Schiphol Plaza

Cycling

Cycling is a fun, efficient and easy way of getting around Amsterdam, just like the locals do! With bicycle rental shops all over the city, it's quite simple to pedal away. And it's quite safe if you follow a few simple rules!

Here are a few basic pointers to keep in mind after hiring your bike:

- Use the bicycle lane on the right-hand side of the road, marked out by white lines and bike symbols
- Adhere to all traffic lights and signs
- Do not cycle on footpaths, in shopping streets, on pavements and motorways
- Make sure you signal when turning by putting your hand out
- Be careful not to get your wheels stuck in the tram rails, cross the rails at a steep angle
- Always lock your bike up and attach it to something secure and immovable, preferably a bike rack

Also, follow any instructions the vendor might give you to park and lock-up the bike in authorised locations only.

MacBike offers a free multi-lingual leaflet on how to cycle safely through Amsterdam.



Hotel booking

NH Barbizon Palace Hotel, Amsterdam

Prins Hendrikkade, 59-72 1012 AD Amsterdam (Nederland)

Tel. +31.20.5564564 | Fax: +31.20.6243353 | E-mail: nhbarbizonpalace@nh-hotels.com



The five-star NH Barbizon Palace is located in the heart of old Amsterdam and the famous sights are easily reachable on foot or by public transport. The hotel is directly opposite the Central Station of Amsterdam and 5 minutes walk from Dam Square. The Red Light District and Chinatown are also nearby. The hotel is uniquely composed of nineteen 17th century houses with old Amsterdam architecture and a fifteenth-century chapel which serves as a conference room. Besides 274 rooms the NH Barbizon Palace contains a fitness room, sauna with a relaxation room. Enjoy breakfast, lunch or dinner in Hudson's Terrace & Restaurant, located in the middle of the bright and spacious hotel lobby or dine in the elegant restaurant Vermeer, winner of several international awards.

Booking

Accommodation and congress venue

The Local Organising Committee has already booked rooms at The Barbizon Palace Hotel, Amsterdam.

For hotel reservations you are requested to arrange for your personal reservation with regard to arrival date, number of nights, special requests. You can make your hotel reservation directly <http://www.nh-hotels.com/events/en/event-detail/8218/nki.html>

Social events

Board Dinner - June 15

OECI Board members, informal dinner

Blauw aan de wal

In the heart of Amsterdam, near to the hotel, is a small alley that leads to this charming oasis, complete with the innocent chirping of birds. "Blue on the Quay" is set in a courtyard that once belonged to the Bethanienklooster monastery; it now offers a restful ambience with multiple dining areas, each with a unique and serene view. Original wood floors and exposed-brick walls hint at the building's 1625 origins.



Special Guest Dinner - June 16

OECI Board Members and invitees only

Restaurant Vermeer

In a listed building you'll find Restaurant Vermeer, winner of several international Michelin awards and the Gault Milau. Passion and ambition, timeless and classic, bright and attractive; it is all very successfully combined into a savor Mediterranean cuisine in an atmosphere straight from the Golden Age.

In the private dining room you'll enjoy delicious food and outstanding service.



Gala Dinner - June 17

Preceded by a cultural get together
OECI Board Members, OECI Full- or Associated Members,
companions and invitees only
Requires registration!

St. Olof's Chapel

The building dates back to 1440, one of the oldest in Amsterdam, and fell into disrepair in the 19th century and lost its religious character. A fire ravished it in 1966 and as its end drew near a plan arose to restore St. Olof's Chapel to its original state but add the conveniences and comfort of the 20th century. Now the historical importance creates a special atmosphere while modern facilities ensure the guests' comfort.



AGENDIA

Agendia is a commercial-stage molecular diagnostic company focused on the discovery, development and commercialisation of genomic-based diagnostic products to improve the quality of life for cancer patients by providing healthcare professionals with critical information to enable safe and effective personalised treatment. The Company's SymphonyT suite of four complementary breast cancer tests, TargetPrint[®], MammaPrint[®], BlueprintT and TheraPrint[®], provides a comprehensive support system for oncologists to determine whether a breast cancer patient is likely to benefit from hormonal therapy, chemotherapy or targeted therapies, saving patients from unnecessary treatments and lowering healthcare costs. Agendia's lead test, MammaPrint[®], currently the only molecular diagnostic breast cancer recurrence test to receive clearance from the US Food and Drug Administration, gives physicians a tool to clearly and decidedly separate "high" risk from "low" risk recurrence in early stage breast cancer patients, thereby better gauging the "high" risk patients' need for chemotherapy. Agendia is advancing a pipeline of new products, which includes a further extension of its breast cancer suite of tests as well as products for colon cancer and lung cancer. The Company's research and development activities are driven by its deep scientific roots and supported by collaborations with leading academic consortia, cancer centres and pharmaceutical companies.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Amsterdam, the Netherlands, and Irvine, California, United States. For more information, please visit www.Agendia.com.



mammaprint[™] MammaPrint[®]

decoding breast cancer.

MammaPrint[®] is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint[®] identifies patients with early metastasis risk - patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint[®] test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint[®] tests are conducted in Agendia's CAP-accredited and CLIA compliant service laboratories. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

PHILIPS: improving oncology care through innovation

Philips is committed to understanding the cycle of care – from disease prevention, diagnosis, to treatment, monitoring and health management – and to using that understanding to develop meaningful innovations that deliver value to the patient and the clinician. Our goal is to improve speed, accuracy and quality of diagnosis and therapy to enable the caregiver to find the cancer sooner and select more targeted more personalized therapies. It also means making an impact wherever care happens, not only within the hospital – critical care, emergency care and surgery – but, as importantly, in the home, for patients managing chronic conditions.

Philips has applied its market leadership and experience in oncology to pursue powerful, differentiated solutions for cancer treatment that go far beyond the traditional lens of imaging systems. Philips' value proposition for cancer treatment extends from hospital to home and is marked by innovations across the frontiers of care. Advances in interventional oncology, radiation oncology, clinical informatics and targeted image guided drug delivery are among the many areas where we are breaking ground in cancer care and creating a more people focused healthcare for the future. Our new CT, MR, PET-CT and PET-MR solutions, as well as our HIFU-MR and Mammography propositions are recent examples of our way forward.



Pfizer Oncology dedicates itself to develop and produce medication fighting cancer. Together with experts all over the world Pfizer Oncology works on innovative cancer treatment. Research does not only concentrate on breast- and lungcancer, but also innovates on not as frequent occurring tumor types like renal cell carcinoma, gastrointestinal stromal tumor, hematologic malignancies. The product portfolio now contains medication like Sutent, Aromasin and Torisel. Medication that applies to angiogenesis, immune system, signal transduction and DNA synthesis is in development at this moment.

Our goal is to improve the prognosis and quality of life of the patient by providing innovative medication. Furthermore we focus on training physicians, pharmacists and nurses, information supply and other support and patient care.

We contribute to the scientific knowledge and strive to translate this knowledge in genuine value that enhances the treatment of cancerpatients.

OECE EXTENDED BOARD

President: M.A. Pierotti

President elect: Wim van Harten

Members: Julio Celis, Josè Laranja Pontes, Ulrik Ringborg, Guy Storme

Coopted Members: Dominique de Valeriola, Lisa Licitra,

Antonio Llombart-Bosch, Claudio Lombardo, Gordon McVie,

Angelo Paradiso, Peter Riegman, Mahasti Saghatchian, Thomas Tursz

AMSTERDAM 2011 SCIENTIFIC COMMITTEE

Marco A. Pierotti, INT, Italy

Wim van Harten, NKI, The Netherlands

Anton Berns, NKI, The Netherlands

René Bernards, NKI, The Netherlands

Julio Celis, Danish Cancer Society, Denmark

Josè L. Pontes, Instituto Portugues de Oncologia, Portugal

Ulrik Ringborg, Karolinska Institute, Sweden

Guy Storme, UZ Brussel, Belgium

AMSTERDAM 2011 ORGANISING COMMITTEE

Claudio Lombardo - OECE/EEIG Liaison Office

IST - National Institute for Cancer Research

Genoa, Italy

Tel: +32 2 512 01 46

Email: oece@oece.eu - <http://www.oece.eu>

Georgette van Velzen - The Netherlands Cancer Institute

Amsterdam, The Netherlands

Tel: +31 20 5129022

Email: g.v.velzen@nki.nl - <http://www.oece-amsterdam2011.com>

OECE OFFICE

AMSTERDAM: Georgette van Velzen

BARI: Silvana Valerio

BRUSSELS: Lutgarde D'Hauwers

GENOA: Sergio Bottero, Francesca d'Alessandro, Germana Gianquinto,

Margherita Marincola, Giorgia Pesce

GRONINGEN: Femke Boomsma, Henk Hummel

MILAN: Daniela Majerna

PARIS: Cécile Tableau